# How Federal Cannabis Rescheduling Could Be Impacted by Attorney General Changes > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/federal-cannabis-rescheduling-impacts-attorney-general-changes/ > **Published:** 2026-04-02T12:52:13-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:07:23-04:00 > **Clinical Summary:** Explore how federal cannabis rescheduling impacts may shift if a new attorney general replaces Bondi, affecting policy and clinical access. --- ✦ New CED Clinical Relevance #45 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyResearchIndustry Clinical Summary # Clinical Summary The potential replacement of the Attorney General could significantly impact the federal rescheduling of marijuana, which is currently under administrative review by the DEA. The proposed successor has a documented history of opposing [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) efforts, including voting against New York’s medical cannabis bill in 2014, suggesting potential resistance to rescheduling initiatives that would expand access and research opportunities. Federal rescheduling of cannabis from Schedule I would have substantial clinical implications, including reduced barriers to prescribing, enhanced research capacity, and improved insurance coverage for patients with eligible conditions. Changes in federal leadership could either accelerate or substantially delay the ongoing rescheduling process, affecting the regulatory landscape for cannabis medicine over the coming years. Clinicians should monitor developments in federal cannabis policy, as shifts in Attorney General positions may alter access to cannabis-based therapeutics and the evidence base supporting their use. Physicians should remain informed about the current rescheduling status and communicate with patients about potential changes that could affect their treatment options and medication costs. Dr. Caplan’s Take “If cannabis remains Schedule I, we’re locked out of the federal research infrastructure that could finally answer the clinical questions my patients are already asking me about dosing, drug interactions, and long-term safety, and that gap between what patients are using and what we can actually study creates real clinical liability.” Clinical Perspective The potential rescheduling of cannabis at the federal level faces significant uncertainty given shifts in executive branch leadership and the ideological positions of key appointees overseeing drug policy. While rescheduling could have meaningful implications for research access, clinical standardization, and interstate commerce in cannabis products, political volatility and individual decision-makers’ historical voting patterns introduce considerable unpredictability into the timeline and outcome. Healthcare providers should recognize that current state-level legal variability will likely persist, meaning clinical guidance on cannabis use must remain responsive to local regulations while grounded in the still-limited evidence base for therapeutic applications. Rather than awaiting federal clarity that may be years away, clinicians are prudent to establish their own evidence-based frameworks for discussing cannabis with patients, documenting indications carefully, and staying informed about evolving research on both efficacy and harms across different patient populations and products. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Marijuana+Rescheduling+Could+Be+Impacted+If+Trump+Replaces+Bondi+As+Attorney+General+...+%40drcaplan&url=https%3A%2F%2Fwww.marijuanamoment.net%2Fmarijuana-rescheduling-could-be-impacted-if-trump-replaces-bondi-as-attorney-general-with-zeldin%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.marijuanamoment.net%2Fmarijuana-rescheduling-could-be-impacted-if-trump-replaces-bondi-as-attorney-general-with-zeldin%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Marijuana+Rescheduling+Could+Be+Impacted+If+Trump+Replaces+Bondi+As+Attorney+General+...+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.marijuanamoment.net%2Fmarijuana-rescheduling-could-be-impacted-if-trump-replaces-bondi-as-attorney-general-with-zeldin%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.marijuanamoment.net/marijuana-rescheduling-could-be-impacted-if-trump-replaces-bondi-as-attorney-general-with-zeldin/](https://www.marijuanamoment.net/marijuana-rescheduling-could-be-impacted-if-trump-replaces-bondi-as-attorney-general-with-zeldin/) Further Reading Evidence Watch[Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta-analysis.](https://cedclinic.com/cannabis-use-disorder-treatment-research/) CED Clinic BlogFirst stop, the Moon. Next stop, Mars? Why Nasa’s mission matters Cannabis Policy Wire[CED Regulatory Digest, Since Last Digest, 2 items](https://cedclinic.com/ced-regulatory-digest-since-last-digest-2-items/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [How could new attorney general impact cannabis rescheduling? (Newsletter: April 3, 2026)](https://cedclinic.com/attorney-general-cannabis-policy-impact-rescheduling-2026/) A detailed newsletter exploring the potential effects of a new attorney general on cannabis rescheduling policies. [Read the Newsletter](https://cedclinic.com/attorney-general-cannabis-policy-impact-rescheduling-2026/) [Tilray Brands Positioned for U.S. Expansion Amid Historic Cannabis Rescheduling](https://cedclinic.com/tilray-u-s-expansion-cannabis-rescheduling/) Insights into how historic cannabis rescheduling could impact major cannabis companies like Tilray. [Learn More](https://cedclinic.com/tilray-u-s-expansion-cannabis-rescheduling/) [State of Texas: Marijuana reclassification could expand medical research – Yahoo](https://cedclinic.com/texas-marijuana-reclassification-expand-medical-research/) An article discussing how marijuana reclassification might expand medical research opportunities in Texas. [Explore the Article](https://cedclinic.com/texas-marijuana-reclassification-expand-medical-research/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).